• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Specific residues of PB2 and PA influenza virus polymerase subunits confer the ability for RNA polymerase II degradation and virus pathogenicity in mi

tetano

Editor, Senior Moderator
J Virol. 2014 Jan 8. [Epub ahead of print]
Specific residues of PB2 and PA influenza virus polymerase subunits confer the ability for RNA polymerase II degradation and virus pathogenicity in mice.
Llompart CM, Nieto A, Rodriguez-Frandsen A.
Author information
Abstract

Influenza virus transcription requires a functional coupling with cellular transcription for the cap-snatching process. Despite this fact, RNA polymerase II (RNAP II) is degraded during infection in a process triggered by the viral polymerase. Reassortant viruses from A/PR/8/34 (PR8) strain that induce (hvPR8) or not (lvPR8) RNAP II degradation, led to the identification of PA and PB2 subunits as responsible for the degradation process. Three changes in PB2 sequence (I105M, N456D and I504V) and two in PA (Q193H, I550L) differentiate PA and PB2 of lvPR8 from hvPR8. Using recombinant viruses we have observed that changes at positions 504 of PB2 together with 550 of PA confer the ability to lvPR8 for RNAP II degradation and conversely abolish hvPR8 degradation capacity. Since hvPR8 is more pathogenic than lvPR8 in mice, we tested the potential contribution of RNAP II degradation in a distant viral strain such as the 2009 pandemic A/California/04/09 (CAL) virus whose PA and PB2 subunits are of avian origin. As in the hvPR8 virus, mutations at positions 504 of PB2 and 550 of PA in CAL virus abolished its RNAP II degradation capacity. Moreover, in an in vivo model the CAL-infected mice lost more body weight and 75% lethality was observed in this situation compared with 100% survival on mutant CAL- or mock-infected animals. These results confirm the involvement of specific PB2 and PA residues in RNAP II degradation, which correlates with pathogenicity in mice of viruses containing human or avian polymerase PB2 and PA subunits.

PMID:
24403580
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24403580
 
Back
Top Bottom